Value through Innovation27 July 2016

What is a lay summary?

To view this video in other translations click on the language below:
Chinese (simplified)
Chinese (traditional)
Portuguese (Brazilian)

Clinical Study Results

  • MOBIC ® - Respiratory Tract Infections
    Clinical Study Number 107.250
    Study Indication Respiratory Tract Infections
    Product MOBIC ®
    Generic Name Meloxicam
    Lab Code
    Clinical Phase IV
    Study Title

    Randomized, open-label, controlled trial to assess the clinical efficacy and safety of meloxicam suspension 0.25 mg/kg/day once a day, versus diclofenac 1 mg/kg/day twice a day or nimesulide 4 mg/kg/day twice a day, for five days in the treatment of patients with acute, non-bacterial pharyngitis, pharyngotonsillitis or laryngitis

    Study Document
    Trial synopsis 107.250 english